Statsols Blog

Top 10 Corporate Clinical Trial Sponsors of 2016

Following on from our previous blog post, The Most Popular Clinical Trial Drugs of 2016, we thought it would be a good idea to take a closer look at the Top 10 Corporate Clinical Trial Sponsors of 2016.

In this post, we explore these Top 10 companies, looking at their developmental histories as well as the drugs they have developed and the number of subjects required for their 2016 registered trials.

Topics: Power & Sample Size Clinical Trials Clinical Trial Sponsors Top10

Key Trends In Sample Size Determination. Part 3/3

In part 3/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size cost consideration, integration

Key Trends In Sample Size Determination. Part 2/3

In part 2/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size adaptive trials sample size restimation

Key Trends In Sample Size Determination. Part 1/3

In part 1/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size Parameter Estimates

Most Popular Clinical Trial Drugs of 2016

Currently there are over 205,000 registered clinical trials underway throughout the globe. In 2016 over 14,000 new trials were initiated and we thought it would be useful to look at the top drugs under investigation for the year just past.

Topics: Power & Sample Size Phase III Failure

15 Ways to Reduce Sample Size In Clinical Trials

How do you reduce sample size in clinical trials? Reducing sample size without losing power can be accomplished in one of three principles. This paper examines these methods and demonstrates 15 ways to reduce sample size in clinical trials.

Topics: Power & Sample Size Clinical Trials Reduce Sample Size

Why do phase III clinical trials fail?

Why do Phase III clinical trials fail and how can we improve them? Dr. Grignolo, PhD, Corporate Vice President of PAREXEL International, the multinational life sciences consulting firm, recently examined this issue in a paper titled: Phase III Trial Failures: Costly, But Preventable.

We have reviewed this journal and brought you the primary findings as they appeared in Applied Clinical Trials Volume 25, Issue 8 and also on appliedclinicaltrialsonline.com.

Topics: Power & Sample Size Phase III Failure

Making it personal: N-of-1 trials, allowing for individuality but not overdoing it

N-of-1 trials are the application of the machinery of randomised clinical trials to the individual patient. Episodes of treatment rather than individual patients become the fundamental unit of inference and patients are repeatedly randomised to an experimental and a control treatment (say) in order to establish the effect of treatment. Popular designs involve cycles of episodes of treatment with the patient being assigned to a random order within cycles. (Continued below)

Topics: Power & Sample Size Clinical Trials N-of-1 Trials Stephen Senn